title: Results of surgical, laparoscopic, and percutaneous treatment for hydatid disease of the liver: 10 years experience with 355 patients.
abstract: Selection of the most appropriate treatment to obtain the best results with the lowest rate of recurrence and minimal morbidity and mortality is mandatory for the management of hepatic hydatid disease. The surgical approach is the mainstay of treatment, and there has been a tendency toward laparoscopic surgery and, more recently, percutaneous treatment (PT), which has become increasingly popular with revolutions in techniques. We aimed to evaluate the results of current therapeutic methods in the context of a 10-year single-institution experience. Between 1992 and 2003, 355 patients with 510 hydatid cysts of the liver were treated by open operation, laparoscopic surgery, or PT. The series included 128 females and 227 males ranging in age from 10 years to 73 years. Preferred treatment modalities, perioperative complications, interventions, recurrences, and length of hospital stay were retrospectively analyzed. There were two postoperative deaths (1.08%) in the open surgery group. Biliary leakage was observed in 28 patients treated with open surgery, in 10 patients after PT, and in 2 after laparoscopic treatment. Recurrence rates were 16.2%, 3.3%, and 3.5% after open surgery, laparoscopic surgery, and percutaneous treatment, respectively. Characteristics of the cyst, presence of cystobiliary communications, and the availability of a multidisciplinary team are the factors that we believe directly affect the results. Radical surgery can be done safely for suitable cases; conventional procedures are associated with greater morbidity. Laparoscopic surgery seems effective and safe, with low morbidity and recurrence rates for type I-III cysts in accessible localizations. Our experience with PAIR (puncture, aspiration, injection, and reaspiration) and catheterization provides evidence that the procedure is an effective and safe option.
authors.affiliation: Department of Surgery, Gulhane School of Medicine, Ankara, 06018, Turkey. gyagci@gata.edu.tr
authors.forename: Gokhan
authors.initials: G
authors.lastname: Yagci
authors.forename: Bahri
authors.initials: B
authors.lastname: Ustunsoz
authors.forename: Nihat
authors.initials: N
authors.lastname: Kaymakcioglu
authors.forename: Ugur
authors.initials: U
authors.lastname: Bozlar
authors.forename: Semih
authors.initials: S
authors.lastname: Gorgulu
authors.forename: Abdurrahman
authors.initials: A
authors.lastname: Simsek
authors.forename: Ali
authors.initials: A
authors.lastname: Akdeniz
authors.forename: Sadettin
authors.initials: S
authors.lastname: Cetiner
authors.forename: Turgut
authors.initials: T
authors.lastname: Tufan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015766:Albendazole / Q000008:administration & dosage; D000871:Anthelmintics / Q000008:administration & dosage; D002404:Catheterization; D002648:Child; D004322:Drainage; D004444:Echinococcosis, Hepatic / Q000628:therapy*; D000431:Ethanol / Q000008:administration & dosage; D005260:Female; D006498:Hepatectomy; D006801:Humans; D010535:Laparoscopy; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D012997:Solvents / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000871:Anthelmintics; D012997:Solvents; D000431:Ethanol; D015766:Albendazole